Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03444610
Other study ID # IRB 2017-63
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date May 31, 2018
Est. completion date March 31, 2019

Study information

Verified date April 2023
Source King Faisal Specialist Hospital & Research Centre, Jeddah
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Blood transfusion is very lengthy procedure and consumes a substantial time from patients and health care providers. On average, it may take most if not all the working day which leads to significant constrains on hospital bed utilization. It starts from pre-transfusion testing, clinical assessment, actual administration of blood and post-transfusion care. The main bulk of this procedure is usually related to administration of the blood which typically given over 3 hours (5ml/kg/hour), although there is no strong evidence to support that. Indeed, it has been accepted as standard of care to transfuse blood over short time as in emergency situations. OBJECTIVE: To determine the maximum tolerated blood transfusion rate that can be safely delivered in patient who required blood transfusion i.e. transfusing blood over short time. METHOD: This is a phase I, open label, nonrandomized, prospective and rate-finding study. A well-known dose escalation design called 3+3 design will be used to identify the maximum tolerated rate. To assure the safety of such procedure, blood transfusion rate will be escalated very slowly by 1 ml/kg/hour for each cohort until rate-limiting toxicities or maximum of 10ml/kg/hour.


Description:

Blood transfusion is the mainstay of care for patients with different types of chronic severe anemia like thalassemia major. However, it is associated with serious risks and complications. In addition, blood transfusion is a lengthy procedure starting from pre-transfusion testing, clinical assessment, actual administration of blood and post-transfusion care. The main bulk of this procedure is usually related to administration of the blood which typically given over 3 hours (5ml/kg/hour) or even longer in certain cases. On average, such procedure may take most if not all the working day which leads to significant constrains on hospital bed utilization. Also, it is a significant burden on the patient and his/her family to comply with chronic transfusion program. As consequences, this leads to repeated absences from work or school. Although, it is the standard of care to infuse blood at rate of 5ml/kg/hour, there is no strong evidence to support that especially in pediatric population. Indeed, it has been accepted as standard of care to transfuse blood over short time in certain cases. For instance, in an emergency situation, it is allowable to infuse blood over less than one hour. Infusion of stem cells is allowed to be given over one hour as well without a major adverse event. In addition, blood donation is usually done over 30 - 60 minutes. As such, the goal for conducting this study is to find out if we can transfuse blood over the short time without causing any harm. Transfusion associated circulatory overload (TACO) is one of the complications of blood transfusion and known to occur more in adult patients with specific risk factors. TACO is very rare phenomenon in pediatric patients with normal underlying cardiorespiratory functions. In Literature review in pediatrics there was only one case report and that patient had a significant other co-morbidities and risk factors. In our study, there will be many safety measures taking in our consideration starting by very selective criteria to roll the patients in the study with clear inclusion and exclusion points. Blood transfusion rate determine during the study and will be escalated by 1ml/kg per each cohort only and before starting the blood transfusion vital signs will be taken then 15 minutes after blood transfusion running and by the end of the procedure so there will be 3 times documented vital signs and for more safety issue the patients will be attached to cardiopulmonary monitoring during the whole procedure. Our patients will have ECHO pre-and post-transfusion to detect right ventricle load. Patients will have Brain natriuretic peptide (BNP) level will be done before and after finishing of blood transfusion. Then at the end, 24 hours post transfusion evaluation will be done for all patients in the study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 31, 2019
Est. primary completion date February 28, 2019
Accepts healthy volunteers No
Gender All
Age group 3 Years to 14 Years
Eligibility Inclusion Criteria: - Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases. - Age range of 3.0-14 years, inclusive, at the time of study entry. - Parent or guardian willing and able to provide informed consent. - Ability to comply with study-related treatments, evaluations, and follow-up. - Normal Echo study that had been done in the last year. Exclusion Criteria: - Inability to receive or tolerate chronic red blood cell (RBC) transfusion therapy, due to any of the following: - Multiple RBC alloantibodies making cross-matching difficult or impossible. - RBC autoantibodies making cross-matching difficult or impossible. - Life threatening condition like shock. - Hemodynamically unstable. - Hypoxia with oxygen saturation less than 92% on room air. - Any patient with signs of respiratory distress (using accessory muscle or acting ala nasi). - Fluid balance more than 1 liter. - Known severe allergy (anaphylaxis) to blood transfusion. - Previous history of Transfusion associated circulatory overload (TACO). - Heart failure or poor ejection fraction less than 60%. - Current use of therapeutic agents for heart failure or arrhythmia. - Newly diagnosed with active cancers in the 1st week of induction therapy. - Severe anemia- Hb <6gm/dl at the day of transfusion. - Serum creatinine more than twice the upper limit for age.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood transfusion escalation rate
3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Centre, Jeddah

Outcome

Type Measure Description Time frame Safety issue
Primary can we transfuse blood over shorter period? primary out come is transfusion associated circulatory overload(TACO), The Frequency will be used in the study to measure the primary outcome (TACO). 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03885570 - Blood Transfusion Management in Patients With Mitral Valve Replacement in China
Recruiting NCT06023056 - Hepatitis B Vaccination After Neonatal Surgery
Completed NCT04127825 - Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cardiac Surgery N/A
Recruiting NCT03975894 - TAPS2 Transfusion Antenatally in Pregnant Women With SCD Phase 2
Recruiting NCT06358079 - Re-infusion of Unwashed Shed Blood During Off-pump Surgery N/A
Recruiting NCT03814772 - To Establish a Blood Transfusion Prediction Model for Liver Transplantation Patients Based on PBM
Not yet recruiting NCT06244264 - The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis N/A
Completed NCT05314582 - Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Completed NCT05922163 - Blood Transfusion Education Using Blended Virtual Reality and Simulation for Nursing Undergraduate Students N/A
Not yet recruiting NCT06443515 - Respiratory Trends During Blood Transfusions in Newborns. N/A
Completed NCT03146455 - Thromboelastography Normal Reference Values in China Hunan Province
Completed NCT03767361 - Study the Effect of Blood Transfusion on Oxidant-antioxidant Status in Term and Near-term Neonates Early Phase 1
Completed NCT03643458 - Splanchnic Oxygenation Response to Feeds in Preterm Neonates: Effect of Red Blood Cell Transfusion
Completed NCT03577561 - Proficiency Based Training to Investigate Blood Sampling Errors Including WBIT N/A
Recruiting NCT05227014 - Enhanced Recovery and Patient Blood Management in Colorectal Surgery
Recruiting NCT04980742 - Perioperative Risk Factors of Outcomes for Cardiac Surgery: A Retrospective Study
Recruiting NCT05170633 - Blood Warming in Preterm Infants to Decrease Hypothermia N/A
Completed NCT04866953 - UltraMTP in Adult Trauma Patients Undergoing Surgery Within 24 Hours: Effects on Mortality and Clinical Outcomes
Recruiting NCT03855644 - Blood Transfusion Among Patients With Pelvic Fracture in China
Recruiting NCT04833556 - Perioperative Outcomes of Postpartum Hemorrhage in Patients Undergoing Cesarean Delivery